至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

A trimeric structural fusion of an antagonistic tumor necrosis factor-α mutant enhances molecular stability and enables facile modification

J Biol Chem. 2017-04; 
Inoue M,,, Ando D,, Kamada H,,, Taki S,, Niiyama M, Mukai Y,, Tadokoro T, Maenaka K, Nakayama T,, Kado Y,, Inoue T,, Tsutsumi Y,,, Tsunoda SI
Products/Services Used Details Operation
Bacterial Expression System The gene mutants were fused to the signal peptide (MGWSLILLFLVAVATGVHS) at the N terminus and His tag sequences at the C terminus. Codon usage was optimized for eukaryotic expression (GenScript). Get A Quote

摘要

Tumor necrosis factor-α (TNF) exerts its biological effect through two types of receptors, p55 TNF receptor (TNFR1) and p75 TNF receptor (TNFR2). An inflammatory response is known to be induced mainly by TNFR1, whereas an anti-inflammatory reaction is thought to be mediated by TNFR2 in some autoimmune diseases. We have been investigating the use of an antagonistic TNF mutant (TNFR1-selective antagonistic TNF mutant (R1antTNF)) to reveal the pharmacological effect of TNFR1-selective inhibition as a new therapeutic modality. Here, we aimed to further improve and optimize the activity and behavior of this mutant protein both in vitro and in vivo Specifically, we examined a trimeric structural fusion of R1antTNF, ... More

关键词

PEGylation; R1antTNF; TNF; autoimmune disease; biomaterials; drug design; molecular stability; protein chemical modification; protein design; protein engineering; single chain; thermal shift assay; tumor necrosis factor (TNF)